New drug MTX-439 enters first human safety tests for diabetic kidney disease
NCT ID NCT07473323
First seen Mar 18, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This early-phase study tests the safety of a new drug called MTX-439 in healthy adults and people with diabetic kidney disease. Researchers will give single or multiple doses to see how the body handles the drug and what side effects occur. The study does not aim to treat the disease, but to gather important safety information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
RECRUITINGMelbourne, Victoria, 3002, Australia
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.